Related Experiment Video
Updated: Sep 19, 2025
10:11
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
23.2K
Research progress of B7-H3 in malignant tumors
Shuaixiang Zhao1,2, He Zhang2, Guanning Shang1,2
1The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China.
Frontiers in Immunology
|June 16, 2025
Summary
B7 homolog 3 (B7-H3) is a protein found in tumors that impacts cancer progression and immune response. Targeting B7-H3 shows promise for developing new cancer therapies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- B7 homolog 3 (B7-H3), also known as CD276, is a novel member of the B7 immune protein family.
- B7-H3 exhibits distinct expression patterns in normal versus tumor tissues, correlating with tumor progression.
- It plays a dual role in tumor immunity by activating or inhibiting immune responses via receptor binding.
Purpose of the Study:
- To review the structure, distribution, and functions of B7-H3 in cancer progression.
- To summarize current research on B7-H3-targeting therapeutics and clinical trials.
- To highlight the therapeutic potential of B7-H3 in treating malignant tumors.
Main Methods:
- Literature review of B7-H3 structure, function, and expression.
- Analysis of B7-H3's role in both immune and non-immune cancer-related processes.
- Summary of preclinical and clinical research on B7-H3-targeted therapies.
Main Results:
- B7-H3 influences tumor immune responses and non-immunological functions like migration, angiogenesis, metabolism, and drug resistance.
- Significant differences in B7-H3 expression exist between normal and tumor tissues.
- Ongoing research is advancing the development of B7-H3-targeting drugs.
Conclusions:
- B7-H3 is a critical regulator of malignant tumor progression.
- Targeting B7-H3 offers significant therapeutic potential for various cancers.
- Further research and clinical trials are crucial for realizing B7-H3's full clinical utility.
Related Concept Videos
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K